A spirin is known to reduce the incidence of thrombotic occlusive events such as myocardial infarction and stroke. 1 This effect is considered to be due to the platelet inhibitory action of aspirin, which results from irreversible inhibition of platelet cyclooxygenase activity and thromboxane formation. 2 Thromboxane is a potent agonist and crucial mediator of vascular smooth muscle contraction and platelet aggregation. 3 Recently, however, a more direct effect of aspirin on the integrity of the vascular wall has been reported in studies involving the antioxidant properties of aspirin and the capacity of aspirin to protect endothelial cells from the deleterious effects of hydrogen peroxide and, in particular, from iron-dependent oxygen radical formation. [4] [5] [6] The mechanism responsible for the observed aspirininduced endothelial protection is unknown. From the data published by Podhaisky et al, 6 it appears that cytoprotection by aspirin is a long-term effect that occurs after several hours of pretreatment. Therefore, a possible mechanism might be the induction of genes that protect cells from damage by reactive oxygen species. In recent studies, the induction of ferritin has been shown to provide marked antioxidant cellular protection by rapidly sequestering free cytosolic iron, the crucial catalyst of oxygen-centered radical formation via the Fenton reaction in biological systems. 7, 8 Thus, ferritin, which until then was thought to function merely as a "housekeeper" iron storage protein, has emerged as a critical and fast-acting endogenous cytoprotectant that plays an important role in cellular antioxidant defense mechanisms. 9, 10 Our aim, therefore, was to investigate whether ferritin is a potential site of action for aspirin and to characterize the effect of aspirin on the expression of ferritin in endothelial cells.
Materials and Methods

Materials
Bovine pulmonary artery endothelial cells (ATCC CCL 209) were obtained from the American Type Culture Collection. FBS, DMEM, and penicillin/streptomycin were obtained from GIBCO. Hydrogen peroxide was from Merck. The RNeasy Total RNA-Kit was from Qiagen. The DIG DNA Labeling and Detection Kit, the Chemiluminescence Western Blotting Kit, and ␤-actin cDNA were from Boehringer Mannheim. The 530-bp PstI ferritin H (heavy chain) cDNA fragment was a kind gift from Dr Gaetano Cairo (Centro di Studio sulla Patologia Cellulare, CNR, Milano, Italy). 8 Apoferritin and all other chemicals were bought from Sigma.
Cell Culture
Endothelial cells were maintained and subcultured in DMEM supplemented with 15% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin. 11 The cells were grown in a humidified incubator at 37°C and 5% CO 2 .
Ferritin mRNA Analysis
Ferritin mRNA content was analyzed in endothelial cells grown in 150-mm culture dishes after treatment with control media or aspirin for 6 hours. Total RNA was isolated with the RNeasy Total RNA Kit. RNA (40 g) from each sample was denatured and fractionated by 1% agarose-formaldehyde gel electrophoresis. RNA was visual-ized by ethidium bromide staining, transferred to nylon membranes, and baked for 0.5 hours at 120°C. The membranes were hybridized with a random-primed digoxigenin-labeled cDNA probe for human ferritin H 8 or for ␤-actin according to the DIG System user's guide (Boehringer Mannheim). Afterward, membranes were incubated with the chemiluminescent substrate CSPD (Boehringer Mannheim) and exposed to x-ray film for 2 hours. Equal loading of each lane with RNA was assessed by staining 18S and 28S rRNA with ethidium bromide and by using ␤-actin cDNA. Autoradiographs were quantified by computer-assisted videodensitometry (Eagle Eye II-system, Stratagene). Autoradiograms were scanned by densitometry, and the results were normalized to the ratio of ferritin/␤-actin hybridization seen in control (untreated) cells.
Ferritin Protein Analysis
Endothelial cells were cultured in 6-well plates as described above. After a 6-hour incubation with control media, aspirin, salicylic acid, diclofenac, or indomethacin, cells were washed and extracted as described previously. 12, 13 Desferrioxamine was added to the cells 30 minutes before aspirin. Protein (100 g) was applied to SDS-PAGE. After electrophoresis, protein was transferred to a nitrocellulose membrane, and a polyclonal antibody to human ferritin (Sigma) was used to identify ferritin protein content. Antigen-antibody complexes were visualized with the horseradish peroxidase chemiluminescence system according to the manufacturer's instructions (Boehringer Mannheim). Quantification of ferritin induction was performed using computer-assisted videodensitometry (Eagle Eye II-system, Stratagene).
Cell Viability Analysis
Endothelial cells were seeded at 2ϫ10 4 cells per well in 96-well microtiter plates in 100 L of media containing 15% FBS. After a 48-hour incubation at 37°C, cells reached confluence, and aspirin, apoferritin, or ferritin was added. After a 6-hour incubation, hydrogen peroxide was added to the cells. Incubation was continued for 20 hours, followed by a cytotoxicity assay. Cell viability was measured by staining with crystal violet as previously described. 14 -16 This colorimetric test allows assessment of the remaining viable cells after the incubation procedure. After they were washed with PBS, cells were fixed with methanol for 10 minutes and then stained for 10 minutes with a 0.1% crystal violet solution. After 3 washes with tap water, the dye was eluted with 0.1 mol/L trisodium citrate in 50% ethanol for 10 minutes. Optical density at 630 nm was measured using a microtiter plate reader (Biotek EL 311s).
Results
Aspirin increased ferritin protein synthesis in a concentrationdependent fashion: 2.4Ϯ0.3 (0.03 mmol/L aspirin), 3.6Ϯ0.4 (0.1 mmol/L aspirin), and 4.0Ϯ0.3 (0.3 mmol/L aspirin) (significant for all values: PϽ0.05 for aspirin versus control, 2-tailed t test). The densitometric data are meanϮSEM of 3 independent experiments and represent fold induction versus control (untreated) cells. A representative experiment is shown in Figure 1A . However, mRNA levels of ferritin H remained unaltered in the presence of aspirin ( Figure 1B) . Induction of ferritin protein levels by aspirin (0.3 mmol/L) was time dependent: 1.7Ϯ0.2 (4 hours), 3.5Ϯ0.3 (6 hours), 3.9Ϯ0.4 (8 hours), and 4.6Ϯ0.3 (10 hours) (significant for all values: PϽ0.05 for aspirin versus control, 2-tailed t test). The densitometric data are meanϮSEM of 3 independent experiments and represent fold induction versus control (untreated) cells. A representative experiment is shown in Figure 2A . Over the entire time course assessed, aspirin had no effect on ferritin H mRNA ( Figure 2B ). Ferritin protein induction by aspirin was specific in that other nonsteroidal anti-inflammatory drugs, such as salicylic acid, indomethacin, or diclofenac, failed to alter ferritin protein levels ( Figure 3 ). In the presence of the iron chelator desferrioxamine, aspirin-enhanced ferritin synthesis was abrogated: 3.4Ϯ0. Figure 4 . Preincubating the cells for 6 hours with iron-free apoferritin (1 mg/mL) but not with iron-loaded ferritin (1 mg/mL) reduced hydrogen peroxide-mediated cytotoxicity by 50%, thus mimicking a similar antioxidant effect of aspirin (0.03 mmol/L, toxicity reduction by 57%) under these conditions ( Figure 5 ). Apoferritin, ferritin, or aspirin alone had no significant effect on endothelial cell viability.
Discussion
The present study demonstrates, for the first time, that aspirin induces the synthesis of the antioxidant defense protein ferritin. Ferritin, in addition to serving as an iron reserve for the maintenance of vital cellular functions, sequesters iron that might otherwise catalyze damaging oxidative reactions. This cytoprotective antioxidant role of ferritin has remained largely hypothetical until it was shown that cells overexpressing this protein are more resistant to oxidative injury, 7, 10, 13 whereas organisms lacking a functional ferritin gene are more sensitive to oxidative stress. 17 Using cultured endothelial cells, we observed ferritin induction by aspirin at therapeutically relevant concentrations being achieved in plasma during low-dose antithrombotic dosing regimens. 18, 19 Earlier studies have reported inhibitory effects of aspirin on nuclear factor-B (NF-B, a transcription factor) 20 -22 and on the regulation of genes such as nitric oxide synthase 23, 24 but only at rather high concentrations (2 to 20 mmol/L), which are hardly reached or maintained in plasma even after anti-inflammatory doses of aspirin. Therefore, and in contrast to NF-B or NO synthase, ferritin appears to be a molecular target of aspirin with a particular potential for clinical significance. Moreover, ferritin induction by aspirin might explain earlier observations showing that aspirin is capable of directly protecting cultured endothelial cells from oxidant injury. 6 Interestingly, aspirin-dependent endothelial protection reported by Podhaisky et al 6 was most pronounced when toxicity was induced by exogenous ferrous iron, the main Fenton catalyst of oxygen radical formation in living cells. From the results of the present investigation, it seems plausible that by increasing the synthesis of iron-scavenging ferritin, aspirin may specifically withdraw iron ions from the site of oxygen radical formation and may thus effectively interrupt the reaction cascade leading to oxidative stress and tissue damage. Further support for this hypothesis may be derived from our observation that exogenous iron-free apoferritin but not iron-loaded ferritin reduced hydrogen peroxide-mediated injury in endothelial cells, thus mimicking the protective action of aspirin and demonstrating the antioxidant function of newly synthesized ferritin under these conditions. According to our results, the stimulatory effect of aspirin on the expression of ferritin is confined to the translational level. No detectable increase in ferritin mRNA was measured in the presence of aspirin. The main physiological stimulus of ferritin protein synthesis is known to be free intracellular iron, which binds to and inactivates the endogenous repressor of ferritin translation, the iron regulatory protein. 25 To determine whether aspirin induction of ferritin is related to this pathway or occurs independent of free iron, we performed experiments using the iron chelator desferrioxamine. Coincubation with desferrioxamine completely abolished ferritin induction by aspirin, suggesting that free cytosolic iron is required for this effect and that aspirin increases ferritin synthesis by interacting with and possibly activating the well-known iron-dependent posttranscriptional upregulation of ferritin. 25 Interestingly, the ferritin-inducing effect we report here is specific for aspirin and not elicited by other nonsteroidal anti-inflammatory drugs, such as diclofenac, indomethacin, or salicylate. This finding implies that it is the acetyl group within acetylsalicylic acid that confers the capacity to activate ferritin synthesis and that all other inhibitors of cyclooxygenase tested, including nonacetylated salicylate, do not fulfill the structural requirements necessary to activate ferritin translation. Aspirin has been demonstrated to specifically interact with and show affinity toward iron or iron complexes, 6, 26 and it is therefore conceivable that aspirin accelerates dissociation of the ferritin repressor protein from ferritin mRNA, thus allowing ferritin translation. Clearly, more research is needed in order to further analyze the molecular mechanisms by which aspirin exerts its ferritin-inducing effect.
On the basis of the outcome of recent clinical studies, an increase in cellular iron levels has been suggested as a coronary risk factor that (via enhancing oxidative stress) promotes atherosclerosis and raises the incidence of myocardial infarction. [27] [28] [29] [30] Moreover, elevation of catalytically active iron followed by increased expression of ferritin has been observed in atherosclerotic lesions of patients with coronary heart disease, underlining the in vivo relevance of this antioxidant pathway. 9, 31, 32 There has been dispute about the availability in vivo of uncomplexed iron as a Fenton catalyst for redox-based reactions that induce oxidative stress, and the nature of the pool of nonprotein-bound iron in cells and organelles is ill-defined. 33, 34 However, recent progress in analytical methods has made possible the detection and quantification of nonprotein-bound iron in biological tissues and fluids, including those of human origin, thus confirming the existence of catalytically active ferrous iron in vivo. 35, 36 Other in vivo evidence for the relevance of free or loosely bound iron in promoting damage by radical formation comes from studies showing beneficial and tissue protective effects of metal-chelating agents such as desferrioxamine under pathological conditions involving oxidative stress. 37, 38 In light of our investigations, activation of endogenous iron sequestration could be an important mechanism by which aspirin, in addition to its platelet inhibitory action, protects against myocardial infarction, stroke, and death. Since ferritin is thought to play a broader role in the cellular defense against oxidative injury under inflammatory conditions, 9 it is conceivable that increased ferritin expression may also contribute in general to the anti-inflammatory action of aspirin.
In summary, we have demonstrated for the first time that aspirin at therapeutically relevant concentrations is capable of activating the synthesis of ferritin, a protein with cytoprotective and antioxidant properties. Although, on the molecular level, aspirin appeared to enhance iron-dependent ferritin translation, the exact mechanism of aspirin-dependent ferritin induction is not yet fully understood and is currently being investigated in our laboratory. However, with regard to the functional consequences and considering the comparatively low aspirin concentrations required to trigger ferritin synthesis, it can be concluded that this novel antioxidant pathway may significantly contribute to aspirin-induced prevention of endothelial injury in cardiovascular disease, eg, during atherogenesis and other inflammatory processes.
